Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 43 articles: HTML format

Single Articles

May 2026
1. ZOU T, Minna JD
   Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment.
   J Clin Invest. 2026;136:e206316.
   PubMed     Abstract available
   
   
   
2. ISOMOTO K, Haratani K, Tsujikawa T, Tomida S, et al
   Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC.
   J Clin Invest. 2026;136:e195021.
   PubMed     Abstract available
   
   
   
3. XING W, Zhou Y, Haedicke K, Wang C, et al
   Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.
   J Clin Invest. 2026;136:e196095.
   PubMed     Abstract available
   
   
   April 2026
4. ZHAO Y, Zhou Y, Pan L, Tian GG, et al
   Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance.
   J Clin Invest. 2026;136:e191735.
   PubMed     Abstract available
   
   
   March 2026
5. ZHUANG WT, Pang LL, Hu LY, Liao J, et al
   EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-gamma.
   J Clin Invest. 2026;136:e194377.
   PubMed     Abstract available
   
   
   February 2026
6. BURNS TF, Dacic S, Chakka A, Miller E, et al
   MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.
   J Clin Invest. 2025;136:e194708.
   PubMed     Abstract available
   
   
   
7. LI H, De Santis MC, Tucci FA, Tosoni D, et al
   SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
   J Clin Invest. 2026;136:e192705.
   PubMed     Abstract available
   
   
   
8. GHOSH M, Wu C, Kumar A, Nilsson M, et al
   Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression.
   J Clin Invest. 2025;136:e198418.
   PubMed     Abstract available
   
   
   January 2026
9. KENT JR, Abbott KL, Nordgren R, Deik A, et al
   Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism.
   J Clin Invest. 2026 Jan 27:e198821. doi: 10.1172/JCI198821.
   PubMed    
   
   
   December 2025
10. QIU Z, Song NJ, Li A, Singh D, et al
    PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
    J Clin Invest. 2025 Dec 18:e193354. doi: 10.1172/JCI193354.
    PubMed     Abstract available
    
    
    November 2025
11. HAJI S, Ogawa Y
    TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases.
    J Clin Invest. 2025;135:e198802.
    PubMed     Abstract available
    
    
    
12. LIU B, Dai Y, Wang Z, Song J, et al
    TET3 is a common epigenetic immunomodulator of pathogenic macrophages.
    J Clin Invest. 2025;135:e194879.
    PubMed     Abstract available
    
    
    October 2025
13. DRAGONI F, Sop J, Gurumurthy I, Beckey TP, et al
    Selective targeting of HIV infected clones by cognate peptide stimulation and antiproliferative drugs.
    J Clin Invest. 2025 Oct 21:e197266. doi: 10.1172/JCI197266.
    PubMed     Abstract available
    
    
    
14. ZENG C, Wang X, Zhong J, Zhang Y, et al
    PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.
    J Clin Invest. 2025;135:e191040.
    PubMed     Abstract available
    
    
    
15. RAINES B, Tseng-Rogenski S, Dowdican AC, Peris I, et al
    A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer.
    J Clin Invest. 2025 Oct 14:e193790. doi: 10.1172/JCI193790.
    PubMed     Abstract available
    
    
    September 2025
16. KRATZMEIER C, Taheri M, Mei Z, Lim I, et al
    Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8+ T cell production of CCR5 chemokines.
    J Clin Invest. 2025;135:e191070.
    PubMed     Abstract available
    
    
    August 2025
17. XIONG T, Wang G, Yu P, Li Z, et al
    CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.
    J Clin Invest. 2025;135:e189920.
    PubMed     Abstract available
    
    
    July 2025
18. KIM YS, Nabet BY, Cortez BN, Sun NY, et al
    NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
    J Clin Invest. 2025 Jul 8:e185423. doi: 10.1172/JCI185423.
    PubMed     Abstract available
    
    
    June 2025
19. DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al
    Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV.
    J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
    PubMed     Abstract available
    
    
    
20. LEE S, Park J, Cho S, Kim EJ, et al
    Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells.
    J Clin Invest. 2025;135:e180570.
    PubMed     Abstract available
    
    
    May 2025
21. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    PubMed     Abstract available
    
    
    April 2025
22. O'KEEFE S, Wang Q
    ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non-small cell lung cancer.
    J Clin Invest. 2025;135:e191094.
    PubMed     Abstract available
    
    
    
23. WANG S, Guo H, Fukushima R, Terajima M, et al
    Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
    J Clin Invest. 2025;135:e189197.
    PubMed     Abstract available
    
    
    
24. JIAO M, Guo Y, Zhang H, Wen H, et al
    ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.
    J Clin Invest. 2025;135:e181517.
    PubMed     Abstract available
    
    
    March 2025
25. SHEN S, Zhang Q, Wang Y, Chen H, et al
    Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
    J Clin Invest. 2025;135:e185278.
    PubMed     Abstract available
    
    
    February 2025
26. YU F, Zheng S, Yu C, Gao S, et al
    KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational Modifications in Lung Cancer.
    J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149.
    PubMed     Abstract available
    
    
    December 2024
27. LI D, Geng K, Hao Y, Gu J, et al
    Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
    J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249.
    PubMed     Abstract available
    
    
    October 2024
28. HUANG Q, Tian N, Zhang J, Song S, et al
    Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma.
    J Clin Invest. 2024;134:e178079.
    PubMed     Abstract available
    
    
    September 2024
29. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available
    
    
    June 2024
30. PARDO L, Norman JC
    Targeting the secretory program of 3q-amplified lung cancers.
    J Clin Invest. 2024;134:e181798.
    PubMed     Abstract available
    
    
    May 2024
31. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    PubMed     Abstract available
    
    
    April 2024
32. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    PubMed     Abstract available
    
    
    
33. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    PubMed     Abstract available
    
    
    March 2024
34. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    PubMed     Abstract available
    
    
    
35. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available
    
    
    January 2024
36. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available
    
    
    
37. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available
    
    
    December 2023
38. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available
    
    
    
39. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available
    
    
    November 2023
40. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available
    
    
    October 2023
41. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available
    
    
    
42. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available
    
    
    
43. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum